Can you recommend regulatory analysis blogs for comparing cell and gene therapy CMC perspectives?

Yes — here are some strong regulatory-analysis blogs / insight sources that are useful for comparing cell and gene therapy CMC perspectives across FDA, EMA, and global regulators.

Best blogs and recurring insight sources

1. DIA Global Forum

• Why it’s useful: Frequently publishes practical regulatory analysis on advanced therapies, including CMC, comparability, potency, and platform/manufacturing issues.
• Good for: Cross-functional regulatory thinking and policy trend comparison.
• Website: https://globalforum.diaglobal.org/

2. Regulatory Focus (RAPS)

• Why it’s useful: Strong coverage of FDA and global regulatory developments, with many articles on ATMPs, CMC expectations, and inspection/readiness topics.
• Good for: Interpreting how regulators are thinking and what that means for industry.
• Website: https://www.raps.org/news-and-articles/news-articles

3. The RPM Report

• Why it’s useful: More analytical and often deeper on regulatory policy than a standard news source; useful for FDA/CBER developments.
• Good for: Cell/gene therapy policy, guidance interpretation, and CMC-related regulatory shifts.
• Website: https://www.raps.org/news-and-articles/the-rpm-report

4. BioProcess International / BioPharm International

• Why it’s useful: Not purely regulatory, but often includes CMC-focused thought leadership that bridges development, manufacturing, and regulatory expectations.
• Good for: Comparability, analytics, process development, and manufacturing control strategy.
• Websites:
  • https://www.bioprocessintl.com/
  • https://www.biopharminternational.com/

5. FDA CBER / OTR and Office of Therapeutic Products communications

• Why it’s useful: Not a “blog” in the usual sense, but arguably the most important primary source for U.S. cell and gene therapy CMC perspective.
• Good for: Direct insight into agency priorities, guidance, talks, and public statements.
• Website: https://www.fda.gov/about-fda/center-biologics-evaluation-and-research-cber

6. EMA / CAT updates and advanced therapy pages

• Why it’s useful: Best primary European source for ATMP regulatory and CMC expectations.
• Good for: Comparing EU vs U.S. frameworks.
• Website: https://www.ema.europa.eu/

7. NICHD / regulatory-affairs thought leadership from consulting firms

Several consultancies maintain blogs that are especially good for CMC comparison:

• Pharmapendium / Clarivate
• Parexel
• Tactical / Wuxi / PA Consulting / IQVIA / Charles River thought leadership
• Good for: Practical “what this guidance means” commentary, especially on comparability, potency, analytical strategy, and tech transfer.

If you want the most useful sources specifically for CMC comparison

I’d prioritize these:

1. RAPS / RPM Report
2. DIA Global Forum
3. FDA CBER communications
4. EMA / CAT materials
5. BioProcess International

A good comparison framework for reading these blogs

When comparing cell and gene therapy CMC perspectives, look for coverage of:

• Potency assay expectations
• Comparability after process changes
• Raw material/control strategy
• Vector characterization and release testing
• Cell identity, purity, and viability
• Stability and shelf-life
• Lifecycle management and post-approval changes
• Platform vs product-specific approaches
• U.S. vs EU differences in ATMP classification and expectations

If you want, I can also give you:

• a curated list of specific authors/blog series
• a U.S. vs EU comparison table
• or a short list of the best blogs for gene therapy vs cell therapy separately.